Gout management: Let's get it right this time

Arthritis Care and Research

Volumn 59, Issue 11, 2008, Pages 1535-1537

  Sundy, John S ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; ANTIGOUT AGENT; FEBUXOSTAT; PEGLOTICASE; UNCLASSIFIED DRUG; URATE;

CHRONIC KIDNEY DISEASE; DRESS SYNDROME; DRUG ELIMINATION; DRUG FATALITY; DRUG METABOLISM; DRUG WITHDRAWAL; EDITORIAL; GOUT; HUMAN; HYPERURICEMIA; LIVER FUNCTION; PATIENT EDUCATION; RASH; SIDE EFFECT; URIC ACID BLOOD LEVEL;

ADMINISTRATION, ORAL; ALLOPURINOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION; EUROPE; GOUT; GOUT SUPPRESSANTS; HUMANS; THIAZOLES; URIC ACID; XANTHINE OXIDASE;

EID: 56049096712     PISSN: 21514658     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.24201     Document Type: Editorial

References (19)

1. Schumacher HR Jr. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout. Expert Opin Investig Drugs 2005;14:893-903.
2. Sundy JS, Hershfield MS. Uricase and other novel agents for the management of patients with treatment-failure gout. Curr Rheumatol Rep 2007;9:258-64.
3. Schumacher HR Jr, Becker MA, Wortmann RL, MacDonald PA, Hunt B, Streit J, et al. Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. Arthritis Rheum 2008;59:1540-8.
4. Rundles RW, Metz EN, Silberman HR. Allopurinol in the treatment of gout. Ann Intern Med 1966;64:229-58.
5. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, et al. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med 2005;353:2450-61.
6. Sarawate CA, Brewer KK, Yang W, Patel PA, Schumacher HR, Saag KG, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006;81:925-34.
7. Sarawate CA, Patel PA, Schumacher HR, Yang W, Brewer KK, Bakst AW. Serum urate levels and gout flares: analysis from managed care data. J Clin Rheumatol 2006;12:61-5.
8. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006;33:1646-50.
9. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity: description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984;76:47-56.
10. Kramer HJ, Choi HK, Atkinson K, Stampfer M, Curhan GC. The association between gout and nephrolithiasis in men: the Health Professionals' Follow-Up Study. Kidney Int 2003;64:1022-6.
11. Becker MA, Chohan S. We can make gout management more successful now. Curr Opin Rheumatol 2008;20:167-72.
12. Arromdee E, Michet CJ, Crowson CS, O'Fallon WM, Gabriel SE. Epidemiology of gout: is the incidence rising? J Rheumatol 2002;29:2403-6.
13. Roddy E, Zhang W, Doherty M. The changing epidemiology of gout. Nat Clin Pract Rheumatol 2007;3:443-9.
14. Wallace KL, Riedel AA, Joseph-Ridge N, Wortmann R. Increasing prevalence of gout and hyperuricemia over 10 years among older adults in a managed care population. J Rheumatol 2004;31:1582-7.
15. Okamoto K, Eger BT, Nishino T, Kondo S, Pai EF, Nishino T. An extremely potent inhibitor of xanthine oxidoreductase: crystal structure of the enzyme-inhibitor complex and mechanism of inhibition. J Biol Chem 2003;278:1848-55.
16. European Medicines Evaluation Agency. Adenuric. In: European Public Assessment Report. London: EMEA; 2008.
17. Vasquez-Mellado J, Morales EM, Pacheco-Tena C, Burgos-Vargas R. Relation between adverse events associated with allopurinol and renal function in patients with gout. Ann Rheum Dis 2001;60:981-3.
18. Zhang W, Doherty M, Pascual E, Bardin T, Barskova V, Conaghan P, et al, and the EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part I. Diagnosis: report of a task force of the Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1301-11.
19. Zhang W, Doherty M, Bardin T, Pascual E, Barskova V, Conaghan P, et al, and the EULAR Standing Committee for International Clinical Studies Including Therapeutics. EULAR evidence based recommendations for gout. Part II. Management: report of a task force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). Ann Rheum Dis 2006;65:1312-24.